Scientific Publications

The number of peer-reviewed publications using PamGene's technology is continuing to increase.

Below you will find a selection of scientific publications where PamGene's technology has been applied.

For further information or reprints, please contact us or send an email to

Publications for the Sections:


Reversion of resistance to oxaliplatin by inhibition of p38 MAPK in colorectal cancer cell lines: involvement of the calpain / Nox1 pathway.
Chocry M, Leloup L, Kovacic H. Oncotarget. 2017 Oct 10;8(61):103710-103730
Large-scale reduction of tyrosine kinase activities in human monocytes stimulated in vitro with N. meningitidis.
Gopinathan U, Redalen KR, Trøseid AM, Kierulf P, Brandtzaeg P, Ree AH, Berg JP, Øvstebø R. ( 2018) PLoS One. Jan 19;13(1):e0181912
A strategy to analyse activity-based profiling of tyrosine kinase substrates in OCT-embedded lung cancer tissue.
Arni S, de Wijn R, Garcia-Villegas R, Bitanihirwe BKY, Caviezel C, Weder W, Hillinger S. (2018)
Anal Biochem. Feb 21;547:77-83
GD1a Overcomes Inhibition of Myelination by Fibronectin via Activation of Protein Kinase A: Implications for Multiple Sclerosis.
Qin J, Sikkema AH, van der Bij K, de Jonge JC, Klappe K, Nies V, Jonker JW, Kok JW, Hoekstra D, Baron W. (2017) J Neurosci. Oct 11;37 (41):9925-9938
Proteomic approach toward determining the molecular background of pazopanib resistance  in synovial sarcoma.
Qiao Z, Shiozawa K, Kondo T. (2017) Oncotarget. Nov 28;8(65):109587-109595


Cdkn2a deficiency promotes adipose tissue browning
Rabhi N, Hannou SA, Gromada X, Salas E, Yao X, Oger F, Carney C, Lopez-Mejia IC, Durand E, Rabearivelo I, Bonnefond A, Caron E, Fajas L, Dani C, Froguel P, Annicotte JS. (2017) Mol Metab. Dec 1. pii: S2212-8778(17)30935-3. 

Ex vivo multiplex profiling of protein tyrosine kinase activities in early stages of human lung adenocarcinoma
Arni S, Nhung Le TH, de Wijn R, Garcia-Villegas R, Dankers M, Weder W and Hillinger S (2017). Oncotarget Aug 2;8(40):68599-68613
Open access

Generation of novel patient-derived CIC- DUX4 sarcoma xenografts and cell lines.
Oyama R, Takahashi M, Yoshida A, Sakumoto M, Takai Y, Kito F, Shiozawa K, Qiao Z, Arai Y, Shibata T, Araki Y, Endo M, Kawai A, Kondo T. (2017) Sci Rep. Jul 5;7(1):4712.

Gene expression profiles and signaling mechanisms in α2B-adrenoceptor-evoked proliferation of vascular smooth muscle cells
Huhtinen A, Hongisto V, Laiho A, Löyttyniemi E, Pijnenburg P, Scheinin M (2017). BMC Systems Biology 11: 65 Epub.
Open access

Kinomic profiling identifies focal adhesion kinase 1 as a therapeutic target in advanced clear cell renal cell carcinoma.
Ghosh AP, Willey CD, Anderson JC, Welaya K, Chen D, Mehta A, Ghatalia P, Madan A, Naik G, Sudarshan S, Sonpavde G. (2017) Oncotarget. Apr 25;8(17):29220-29232.

Cetuximab Prevents Methotrexate-Induced Cytotoxicity in Vitro through Epidermal Growth Factor Dependent Regulation of Renal Drug Transporters.
Caetano-Pinto P, Jamalpoor A, Ham J, Goumenou A, Mommersteeg M, Pijnenburg D, Ruijtenbeek R, Sanchez-Romero N, van Zelst B, Heil SG, Jansen J, Wilmer MJ, van Herpen CML, Masereeuw R. (2017) Mol Pharm. Jun 5;14(6):2147-2157

Molecular mechanism underlying the pharmacological interactions of the protein kinase C-β inhibitor enzastaurin and erlotinib in non-small cell lung cancer cells.
Steen NV, Potze L, Giovannetti E, Cavazzoni A, Ruijtenbeek R, Rolfo C, Pauwels P, Peters GJ. (2017) Am J Cancer Res. Apr 1;7(4):816-830. eCollection 2017.

Description of the EuroTARGET cohort: A European collaborative project on TArgeted therapy in renal cell cancer-GEnetic- and tumor-related biomarkers for response and toxicity.
van der Zanden LF, Vermeulen SH, Oskarsdottir A, Maurits JS, Diekstra MH, Ambert V, Cambon-Thomsen A, Castellano D, Fritsch A, Garcia Donas J, Guarch Troyas R, Guchelaar HJ, Hartmann A, Hulsbergen-van de Kaa C, Jaehde U, Junker K, Martinez-Cardus A, Masson G, Oosterwijk-Wakka J, Radu MT, Rafnar T, Rodriguez-Antona C, Roessler M, Ruijtenbeek R, Stefansson K, Warren A, Wessels L, Eisen T, Kiemeney LA, Oosterwijk E. (2017) Urol Oncol. Apr 3. pii: S1078-1439(17)30109-6.

Kinase analysis of penile squamous cell carcinoma on multiple platforms to identify potential therapeutic targets.
Yang ES, Willey CD, Mehta A, Crowley MR, Crossman DK, Chen D, Anderson JC, Naik G, Della Manna DL, Cooper TS, Sonpavde G. (2017) Oncotarget. Mar 28;8(13):21710-21718. 

Technological advances for interrogating the human kinome.
Baharani A, Trost B, Kusalik A, Napper S. (2017) Biochem Soc Trans. Feb 8;45(1):65-77

Evaluation of a tyrosine kinase peptide microarray for tyrosine kinase inhibitor therapy selection in cancer.
Labots M, Gotink KJ, Dekker H, Azijli K, van der Mijn JC, Huijts CM, Piersma SR, Jiménez CR, Verheul HM. (2016) Exp Mol Med. Dec 16;48(12):e279. 

Clinical and kinomic analysis identifies peripheral blood mononuclear cells as a potential pharmacodynamic biomarker in metastatic renal cell carcinoma patients treated with sunitinib.
Noé G, Bellesoeur A, Thomas-Schoemann A, Rangarajan S, Naji F, Puszkiel A, Huillard O, Saidu N, Golmard L, Alexandre J, Goldwasser F, Blanchet B, Vidal M. (2016) Oncotarget. Aug 29. doi: 10.18632/oncotarget.11686.

Pro-survival responses to the dual inhibition of anti-apoptotic Bcl-2 family proteins and mTOR-mediated signaling in hypoxic colorectal carcinoma cells.
Risberg K, Redalen KR, Sønstevold L, Bjørnetrø T, Sølvernes J, Ree AH. (2016) BMC Cancer. Jul 26;16:531. 

Systems medicine approaches for peptide array-based protein kinase profiling: progress and prospects.
Peppelenbosch MP, Frijns N, Fuhler G.(2016) Expert Rev Proteomics.Jun;13(6):571-8.

Mechanistic Parameterization of the Kinomic Signal in Peptide Arrays.
Dussaq A, Anderson JC, Willey CD, Almeida JS. (2016) J Proteomics Bioinform. May;9(5):151-157

Generation of Microtumors Using 3D Human Biogel Culture System and Patient-derived Glioblastoma Cells for Kinomic Profiling and Drug Response Testing.
Gilbert AN, Shevin RS, Anderson JC, Langford CP, Eustace N, Gillespie GY, Singh R, Willey CD. (2016) J Vis Exp. (112). doi: 10.3791/54026.

CDK4 is an essential insulin effector in adipocytes.
Lagarrigue S, Lopez-Mejia IC, Denechaud PD, Escoté X, Castillo-Armengol J, Jimenez V, Chavey C, Giralt A, Lai Q, Zhang L, Martinez-Carreres L, Delacuisine B, Annicotte J-S, Blanchet E, Huré S, Abella A, Tinahones FJ, Vendrell J, Dubus P, Bosch F, Kahn RC and Fajas L. (2016) J Clin Invest. 126(1):335-348

Protein Kinase Activity Decreases with Higher Braak Stages of Alzheimer's Disease Pathology.
Rosenberger AF, Hilhorst R, Coart E, García Barrado L, Naji F, Rozemuller AJ, van der Flier WM, Scheltens P, Hoozemans JJ, van der Vies SM. (2016) J Alzheimers Dis. 49(4):927-43.

NF-κB drives acquired resistance to a novel mutant-selective EGFR inhibitor.
Galvani E, Sun J, Leon LG, Sciarrillo R, Narayan RS, Sjin RT, Lee K, Ohashi K, Heideman DA, Alfieri RR, Heynen GJ, Bernards R, Smit EF, Pao W, Peters GJ, Giovannetti E. Oncotarget. 2015 Dec 15;6(40):42717-32

STAT5-regulated microRNA-193b controls haematopoietic stem and progenitor cell expansion by modulating cytokine receptor signalling.
Haetscher N, Feuermann Y, Wingert S, Rehage M, Thalheimer FB, Weiser C, Bohnenberger H, Jung K, Schroeder T, Serve H, Oellerich T, Hennighausen L, Rieger MA. (2015) Nat Commun. Nov 25;6:8928.

Kinomics alterations in atypical meningioma
Anderson JC, Taylor RB, Fiveash JB, de Wijn R, Gillespie GY, Willey CD (2015) Med Res Arch. (3). doi: 10.18103/mra.v0i3.104.

Novel EPHB4 Receptor Tyrosine Kinase Mutations and Kinomic Pathway Analysis in Lung Cancer.
Ferguson BD, Tan YH, Kanteti RS, Liu R, Gayed MJ, Vokes EE, Ferguson MK, Iafrate AJ, Gill PS, Salgia R. (2015) Sci Rep. 5:10641. doi: 10.1038/srep10641.
Open access

High Throughput Kinomic Profiling of Human Clear Cell Renal Cell Carcinoma Identifies Kinase Activity Dependent Molecular Subtypes.
Anderson JC, Willey CD, Mehta A, Welaya K, Chen D, Duarte CW, Ghatalia P, Arafat W, Madan A, Sudarshan S, Naik G, Grizzle WE, Choueiri TK, Sonpavde G.  (2015) PLoS One. Sep 25;10(9):e0139267. doi: 10.1371/journal.pone.0139267. eCollection 2015.

Tumor phosphatidylinositol 3-kinase signaling in therapy resistance and metastatic dissemination of rectal cancer: Opportunities for signaling-adapted therapies.
Ree AH, Flatmark K, Saelen MG, Folkvord S, Dueland S, Geisler J, Redalen KR. (2015) Crit Rev Oncol Hematol. 95: 114-124

The protective effect of p16INK4a in oral cavity carcinomas: p16Ink4A dampens tumor invasion-integrated analysis of expression and kinomics pathways.
Isayeva T, Xu J, Ragin C, Dai Q, Cooper T, Carroll W, Dayan D, Vered M, Wenig B, Rosenthal E, Grizzle W, Anderson J, Willey CD, Yang ES, Brandwein-Gensler M. (2015) Mod Pathol. 28 (5): 631-53. 

Kinomic profiling of electromagnetic navigational bronchoscopy specimens: a new approach for personalized medicine.
Anderson JC, Minnich DJ, Dobelbower MC, Denton AJ, Dussaq AM, Gilbert AN, Rohrbach TD, Arafat W, Welaya K, Bonner JA, Willey CD. (2014) PLoS One.  Dec 30;9(12):e116388

Development of a Sox2 reporter system modeling cellular heterogeneity in glioma.
Stoltz K, Sinyuk M, Hale JS, Wu Q, Otvos B, Walker K, Vasanji A, Rich JN, Hjelmeland AB, Lathia JD.  (2014) Neuro Oncol. Nov 21. Mar;17(3):361-71

Combinatorial therapy with tamoxifen and trifluoperazine effectively inhibits malignant peripheral nerve sheath tumor growth by targeting complementary signaling cascades.
Brosius SN, Turk AN, Byer SJ, Longo JF, Kappes JC, Roth KA, Carroll SL. (2014) J Neuropathol Exp Neurol. 73 (11): 1078-90.

Modulation of signaling enhances the efficacy of the combination of satraplatin and erlotinib.
Avan A, Adema AD, Hoebe EK, Huijts CM, Avan A, Veal GJ, Ruijtenbeek R, Wosikowski K, PetersGJ. (2014) Curr Drug Targets. 15 (14):1312-21.

The JH2 domain and SH2-JH2 linker regulate JAK2 activity: A detailed kinetic analysis of wild type and V617F mutant kinase domains.
Sanz Sanz A, Niranjan Y, Hammarén H, Ungureanu D, Ruijtenbeek R, Touw IP, Silvennoinen O, Hilhorst R.  (2014) Biochim Biophys Acta. Oct;1844(10):1835-41. 

Increased IRAK-4 Kinase Activity in Alzheimer’s Disease; IRAK-1/4 Inhibitor I Prevents Pro-inflammatory Cytokine Secretion but not the Uptake of Amyloid Beta by Primary Human Glia
Hoozemans JJM, van Haastert ES, Mulder SD, Nielsen HM, Veerhuis R, Ruijtenbeek R, Rozemuller AJM, Hilhorst R, and van der Vies SM. (2014) J Clin Cell Immunol  5:4 243. 
Open access

Kinomic exploration of temozolomide and radiation resistance in Glioblastoma multiforme xenolines.
Anderson JC, Duarte CW, Welaya K, Rohrbach TD, Bredel M, Yang ES, Choradia NV, Thottassery JV, Yancey Gillespie G, Bonner JA, Willey CD. (2014) Radiother Oncol. Jun;111(3):468-74

Altered serine/threonine kinase activity in schizophrenia.
McGuire JL, Hammond JH, Yates SD, Chen D, Haroutunian V, Meador-Woodruff JH, McCullumsmith RE (2014). Brain Res. Jun 3;1568:42-54.

Dramatic antitumor effects of the dual MET/RON small-molecule inhibitor LY2801653 in non-small cell lung cancer.
Kawada I, Hasina R, Arif Q, Mueller J, Smithberger E, Husain AN, Vokes EE, Salgia R. (2014) Cancer Res. Feb 1;74(3):884-95.

Kinome and mRNA expression profiling of high-grade osteosarcoma cell lines implies Akt signaling as possible target for therapy.
Kuijjer ML, van den Akker BE, Hilhorst R, Mommersteeg M, Buddingh EP, Serra M, Bürger H, Hogendoorn PC, Cleton-Jansen AM.  (2014)  BMC Med Genomics.Jan 21;7:4.

​AKN-028 induces cell cycle arrest, downregulation of Myc associated genes and dose dependent reduction of tyrosine kinase activity in acute myeloid leukemia.
Eriksson A, Kalushkova A, Jarvius M, Hilhorst R, Rickardson L, Kultima H, de Wijn R, Hovestad L, Fryknäs M, Oberg F, Larsson R, Parrow V, Höglund M. (2014) Biochem Pharmacol. Jan 15; 87(2): 284-91.

Kinase control of latent HIV-1 infection: PIM-1 kinase as a major contributor to HIV-1 reactivation. 
Duverger A, Wolschendorf F, Anderson JC, Wagner F, Bosque A, Shishido T, Jones J, Planelles V, Willey C. (2014) Cron RQ, Kutsch O. J Virol. Jan;88(1):364-76. 

Generation of Constitutive Active ERK Mutants as Tools for Cancer Research in Zebrafish
Rian H, Krens SFG, Spaink HP, Snaar-Jagalska EB. (2013) ISRN Cell Biology , vol. 2013, Article ID 867613, 11 pages. doi:10.1155/2013/867613

Differential Inhibition of Ex-Vivo Tumor Kinase Activity by Vemurafenib in BRAF(V600E) and BRAF Wild-Type Metastatic Malignant Melanoma.
Tahiri A, Røe K, Ree AH, de Wijn R, Risberg K, Busch C, Lønning PE, Kristensen V, Geisler J. (2013) PLoS ONE. 8(8): e72692. 

Hypoxic tumor kinase signaling mediated by STAT5A in development of castration-resistant prostate cancer. 
Røe K, Bratland Å, Vlatkovic L, Ragnum HB, Saelen MG, Olsen DR, Marignol L, Ree AH. (2013) PLoS ONE . 8(5): e63723. 

Peptide microarrays for profiling of serine/threonine kinase activity of recombinant kinases and lysates of cells and tissue samples.
Hilhorst R, Houkes L, Mommersteeg M, Musch J, van den Berg A, Ruijtenbeek R. (2013) Methods Mol Biol.  977:259-71. 

Development of a microarray detection method for galectin cancer proteins based on ligand binding.
van Hattum H, Martin NI, Ruijtenbeek R, Pieters RJ. (2013) Anal Biochem. Mar 1;434 (1): 99-104.

Optimizing targeted cancer therapy: Towards clinical application of systems biology approaches.
Sikkema AH, den Dunnen WF, Diks SH, Peppelenbosch MP, de Bont ES. Critical Reviews in Oncology/Hematology (2012) 82 171–186

Directed Modulation of Protein Kinase C Isozyme Selectivity with Bisubstrate-Based Inhibitors.
van Wandelen LT, van Ameijde J, Mady AS, Wammes AE, Bode A, Poot AJ, Ruijtenbeek R, Liskamp RM. ChemMedChem. (2012) Dec;7(12):2113-21

Tumor phosphatidylinositol-3-kinase signaling and development of metastatic disease in locally advanced rectal cancer.
Ree AH, Kristensen AT, Saelen MG, de Wijn R, Edvardsen H, Jovanovic J, Abrahamsen TW, Dueland S, Flatmark K. PLoS One. (2012);7(11):e50806.

Effect of antiangiogenic therapy on tumor growth, vasculature and kinase activity in basal- and luminal-like breast cancer xenografts.
Lindholm EM, Kristian A, Nalwoga H, Krüger K, Nygård S, Akslen LA, Mælandsmo GM, Engebraaten O. Mol Oncol. (2012) Aug;6(4):418-27.

Kinomic profiling approach identifies Trk as a novel radiation modulator.
Jarboe JS, Jaboin JJ, Anderson JC, Nowsheen S, Stanley JA, Naji F, Ruijtenbeek R, Tu T, Hallahan DE, Yang ES, Bonner JA, Willey CD. Radiother Oncol. (2012) Jun;103 (3):380-7

Dual inhibition of Jak2 and STAT5 enhances killing of myeloproliferative neoplasia cells.
Bar-Natan M, Nelson EA, Walker SR, Kuang Y, Distel RJ, Frank DA. Leukemia. (2012) Jun;26 (6):1407-10

Protein kinase activity profiling of postmortem human brain tissue.
Hoozemans JJ, Hilhorst R, Ruijtenbeek R, Rozemuller AJ, van der Vies SM. Neurodegener. Dis. (2012) 10(1-4):46-8.

The platelet P2Y(12) receptor contributes to granule secretion through Ephrin A4 receptor.
Tournoij E, Koekman CA, Du VX, Roest M, Ruijtenbeek R, Moll FL, Akkerman JW. Platelets. (2012) Jan 24;23(8):617-25

Targeted therapy selection-based on tumor tissue kinase activity profiles in patients with refractory solid tumors: An exploratory study.
Labots M, Van der Mijn JC, Dekker H, Gotink K, Voebel-de Jong M, Ruijter R, Neerincx M, Pham TV, Van Der Vliet HJ, Jimenez CR, Van Der Hoeven J, Meijer GA, Verheul HM. J Clin Oncol. (2011) May 20;29(15_suppl):e21080.

Peptide arrays for kinome analysis: new opportunities and remaining challenges.
Arsenault R, Griebel P, Napper S. Proteomics. (2011) Dec;11(24):4595-609.

Tumor kinase activity in locally advanced rectal cancer: angiogenic signaling and early systemic dissemination.
Saelen MG, Flatmark K, Folkvord S, de Wijn R, Rasmussen H, Fodstad Ø, Ree AH. Angiogenesis (2011) Dec;14(4):481-9.

The Use of Semi-parametric Mixed Models to Analyze PamChip Peptide Array Data: an Application to an Oncology Experiment.
Thilakarathne PJ, Clement L, Lin D, Shkedy Z, Kasim A, Talloen W, Versele M, Verbeke G. Bioinformatics (2011) Oct 15;27(20):2859-65

Analysis of Jak2 Catalytic Function by Peptide Microarrays: The Role of the JH2 Domain and V617F Mutation.
Sanz A, Ungureanu D, Pekkala T, Ruijtenbeek R, Touw IP, Hilhorst R, Silvennoinen O.  PLoS One. (2011) Apr 18;6(4):e18522.

Focal Adhesion Kinase (FAK) Binds RET Kinase via Its FERM Domain, Priming a Direct and Reciprocal RET-FAK Transactivation Mechanism.
Plaza-Menacho I, Morandi A, Mologni L, Boender P, Gambacorti-Passerini C, Magee AI, Hofstra RM, Knowles P, McDonald NQ, Isacke CM.   J Biol Chem. (2011) May 13; 286 (19): 17292-302.

Identification of new possible targets for leukemia treatment by kinase activity profiling.
Ter Elst A, Diks SH, Kampen KR, Hoogerbrugge PM, Ruijtenbeek R, Boender PJ, Sikkema AH, Scherpen FJ, Kamps WA, Peppelenbosch MP, de Bont ES. Leuk Lymphoma. (2011) Jan; 52 (1):122-30.

Prediction of Response to Preoperative Chemoradiotherapy in Rectal Cancer by Multiplex Kinase Activity Profiling
Folkvord S, Flatmark K, Dueland S, de Wijn R, Grøholt KK, Hole KH, Nesland JM, Ruijtenbeek R, Boender PJ, Johansen M, Giercksky KE, Ree AH. Int J Radiat Oncol Biol Phys. (2010) Oct 1;78 (2):555-62.

Strategies for kinome profiling in cancer and potential clinical applications: chemical proteomics and array-based methods.
Piersma SR, Labots M, Verheul HM, Jiménez CR. Anal Bioanal Chem. (2010) Aug; 397(8): 3163-71.

The phosphatase and tensin homolog regulates epidermal growth factor receptor (EGFR) inhibitor response by targeting EGFR for degradation.
Vivanco I, Rohle D, Versele M, Iwanami A, Kuga D, Oldrini B, Tanaka K, Dang J, Kubek S, Palaskas N, Hsueh T, Evans M, Mulholland D, Wolle D, Rajasekaran S, Rajasekaran A, Liau LM, Cloughesy TF, Dikic I, Brennan C, Wu H, Mischel PS, Perera T, Mellinghoff IK.  Proc Natl Acad Sci USA. (2010) Apr 6;107(14):6459-64.

Triple-negative breast cancer: present challenges and new perspectives.
Podo F, Buydens LM, Degani H, Hilhorst R, Klipp E, Gribbestad IS, Van Huffel S, van Laarhoven HW, Luts J, Monleon D, Postma GJ, Schneiderhan-Marra N, Santoro F, Wouters H, Russnes HG, Sørlie T, Tagliabue E, Børresen-Dale AL; FEMME Consortium. Mol Oncol. (2010) Jun;4 (3):209-29.

Development of selective bisubstrate-based inhibitors against protein kinase C (PKC) isozymes by using dynamic peptide microarrays.
Poot AJ, van Ameijde J, Slijper M, van den Berg A, Hilhorst R, Ruijtenbeek R, Rijkers DT, Liskamp RM. Chembiochem. (2009) Aug 17;10(12):2042-51.

Response prediction to a multitargeted kinase inhibitor in cancer cell lines and xenograft tumors using high-content tyrosine peptide arrays with a kinetic readout.
Versele M, Talloen W, Rockx C, Geerts T, Janssen B, Lavrijssen T, King P, Göhlmann HW, Page M, Perera T.  Mol Cancer Ther. (2009) Jul;8(7):1846-55.

Episodic Src activation in uveal melanoma revealed by kinase activity profiling.
Maat W, el Filali M, Dirks-Mulder A, Luyten GP, Gruis NA, Desjardins L, Boender P, Jager MJ, van der Velden PA.  Br J Cancer. (2009) Jul 21;101(2):312-9.

Peptide microarrays for detailed, high-throughput substrate identification, kinetic characterization, and inhibition studies on protein kinase A.
Hilhorst R, Houkes L, van den Berg A, Ruijtenbeek R.  Anal Biochem. (2009) Apr 15;387 (2): 150-61.

Osteoblast-induced EGFR/ERBB2 signaling in androgen-sensitive prostate carcinoma cells characterized by multiplex kinase activity profiling.
Bratland A, Boender PJ, Høifødt HK, Østensen IH, Ruijtenbeek R, Wang MY, Berg JP, Lilleby W, Fodstad Ø, Ree AH.  Clin Exp Metastasis. (2009) 26(5):485-96.

Kinome profiling in pediatric brain tumors as a new approach for target discovery.
Sikkema AH, Diks SH, den Dunnen WF, ter Elst A, Scherpen FJ, Hoving EW, Ruijtenbeek R, Boender PJ, de Wijn R, Kamps WA, Peppelenbosch MP, de Bont ES. Cancer Res. (2009) Jul 15;69 (14):5987-95.

Intrinsic differences between the catalytic properties of the oncogenic NUP214-ABL1 and BCR-ABL1 fusion protein kinases.
De Keersmaecker K, Versele M, Cools J, Superti-Furga G, Hantschel O.  Leukemia. (2008) Dec; 22(12):2208-16.

Suppressed NFAT-dependent VEGFR1 expression and constitutive VEGFR2 signaling in infantile hemangioma.
Jinnin M, Medici D, Park L, Limaye N, Liu Y, Boscolo E, Bischoff J, Vikkula M, Boye E, Olsen BR. Nat Med. (2008) Nov;14(11):1236-46.

Endogenous phosphotyrosine signaling in zebrafish embryos.
Lemeer S, Ruijtenbeek R, Pinkse MW, Jopling C, Heck AJ, den Hertog J, Slijper M. Mol Cell Proteomics. (2007) Dec;6(12):2088-99.

Protein-tyrosine kinase activity profiling in knock down zebrafish embryos.
Lemeer, S., Jopling, C., Naji, F., Ruijtenbeek, R., Slijper, M., Heck, A. J., and den Hertog, J. PLoS ONE (2007) Jul 4;2(7):e581